Meeting Report
27–30 June 2017 Manila, Philippines
October 2018
This publication was produced at the request of the United States Agency for International Development. It was prepared independently by David Lowe, David Hales, Britt Herstad, Billy Pick, Aisuluu Bolotbaeva, and Gulgun Jonboboeva.
F1000Research 2019, 8:323 Last updated: 17 MAY 2019
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Research Article
PLOS ONE | DOI:10.1371/journal.pone.0164619 October 13, 2016
The KNAP 2018 - 2022 is the second National Nutrition Action Plan that operationalizes the National Food and Nutrition Security Policy 2012 and its implementation framework (NFNSP-IF) 2017–2022.
This report is one of the first major products of the newly established Precision Public Health Metrics unit of the UCN cluster of the WHO Regional Office for Africa. The report presents national trends in communicable and non-communicable disease burden and control in the WHO African region. It tra...cks progress made with respect to disease burden reduction, elimination and eradication. It also highlights major emerging threats, opportunities and priorities in the fight against commu- nicable and non-communicable diseases in the region. It covers the period 2000-2022, but for some indicators, information is available only up to 2021.
The report shows the number of reported cases for malaria and vaccine preventable diseases (meningitis, measles, yellow fever, pertussis, diphtheria, tetanus, and polio); disease incidence due to HIV, tuberculosis and four major noncommunicable diseases (cardiovas- cular diseases, cancers, diabetes and chronic respira- tory diseases).
more
Guidelines
June 2017
HIV strategic information for impact
Oxford Policy Management (OPM) - APW with UNAIDS (thru TSF)
Zero new HIV infections
Zero Discrimination
Zero AIDS related deaths
Accessed: 04.10.2019
Report of Meeting: 4 November 2014, Roma
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more